With the rapid development of China's pharmaceutical industry and the continuous optimization of pharmaceutical policies, pharmacoeconomic evidence is now playing an increasingly important role in multiple scenarios such as the formulation of pharmaceutical policies, health insurance access, drug pricing and reimbursement decisions. The Center for Pharmacoeconomics Evaluation and Research of China Pharmaceutical University (CPU) and the Young Scholars' Alliance of International Pharmaceutical Business School (YSAIPBS) have invited Prof. Louis Garrison from the University of Washington, USA, to share his latest research results and practical experience. All are welcome to attend!
The event information is as follows:
Topic: The Economics of Pharmaceutical Market Design and Global Differential Pricing.
Time: December 9, 2024 (Monday) 13:30-15:30 pm
Venue: Lecture Hall 111, Economics and Management Building, Jiangning Campus, China Pharmaceutical University.
Speaker: Prof. Louis Garrison
Moderator: Prof. Li Hongchao
Speaker Introduction:
Louis Garrison is Professor Emeritus at the University of Washington, Adjunct Professor at the College of Pharmacy, Terai University, Executive Committee Member of the ACCESS Forum, Academic Collaborator at Analysis Group, Founder and CEO of Global Health Economics, Senior Visiting Fellow at the Institute of Health Economics, London, UK, and ISPOR Policy Outlook Committee Co-Chair (2017-present), ISPOR Health Sciences Policy Committee Chair (2012-2015), Premera Value Assessment Committee Member (2009-present), and other academic positions. He also serves on the boards of the New England Journal of Medicine, Infectious Disease, Value in Health, Health Affairs, Health Care Financing Review, Inquiry. Health Affairs, Health Care Financing Review, Inquiry, Medical Care, Pharmacogenetics, and other international refereed journals. He has published more than 200 SCI/SSCI papers in New England Journal of Medicine, Value in Health, etc. He has participated in the development of a number of international policy frameworks and guidelines, and has co-edited more than 10 important books in the fields of pharmacoeconomics and health technology assessment. His research interests include health technology assessment, innovation value assessment, and pharmacoeconomic evaluation (focusing on the fields of precision medicine and gene therapy).
Moderator Profile:
Hongchao Li, Doctor of Science, Associate Professor, Master Supervisor. Currently, he is the director of Health Economics Teaching and Research Department of International Pharmaceutical Business School of China Pharmaceutical University, the deputy director of Pharmacoeconomics Evaluation Research Center, and the deputy director of Jiangsu Comprehensive Clinical Evaluation Technology Center of Drugs. Main Academic Affiliations: Member of Pharmacoeconomics Committee of Chinese Pharmaceutical Society, Vice Chairman of Pharmacoeconomics Committee of Chinese Association of Traditional Chinese Medicine, Standing Member of Pharmacoeconomics Committee of Chinese Society of Research Hospitals, Standing Member of Health Technology Evaluation Branch of Chinese Pharmaceutical and Biotechnology Association, Secretary General of Pharmacoeconomics Committee of Jiangsu Pharmaceutical Society. His main research interests include pharmacoeconomics evaluation (including health technology assessment and comprehensive clinical evaluation of drugs) and pharmaceutical and health policy analysis and research.
